FDA accepts Biogen Idec BLA for hemophilia B therapy
Using the company’s novel and proprietary monomeric Fc fusion technology, clotting factor rFIXFc provides long-lasting protection from bleeding and reduces the treatment burden associated with hemophilia B. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.